| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
AMPA receptor (noncompetitive allosteric antagonist). No IC50, Ki, EC50, or DC50 values are provided in this manuscript [2].
|
||
|---|---|---|---|
| ln Vitro |
In PANC1 and PaTu-8988t pancreatic cancer cells, treatment with SYM2206 at concentrations ranging from 0 to 100 μM for 72 hours resulted in a dose-dependent inhibition of cell viability as assessed by MTT assays. The compound significantly reduced viability compared to untreated cells at concentrations of 25, 50, and 100 μM (P < 0.05). Representative data are shown in Figure 5D, demonstrating that SYM2206 effectively decreases pancreatic cancer cell survival [2].
|
||
| ln Vivo |
|
||
| Cell Assay |
The cell viability assay was performed using the MTT Cell Proliferation Kit. PANC1 and PaTu-8988t cells were seeded and cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum, 100 μg/ml streptomycin, and 100 U/ml penicillin at 37°C in 5% CO2. Cells were incubated with increasing concentrations of SYM2206 (0–100 μM) for 72 hours. Following incubation, MTT reagent was added according to the manufacturer's instructions, and absorbance was measured to determine cell viability. Results were compared to untreated control cells, and statistical significance was set at P < 0.05 [2].
|
||
| Animal Protocol |
|
||
| References |
Front Cell Neurosci.2018 Oct 11;12:361;Neoplasia.2010 Aug;12(8):659-67.
|
||
| Additional Infomation |
8-(4-aminophenyl)-5-methyl-N-propyl-5H-[1,3]dioxacyclopenteno[4,5-g]phthalazine-6-carboxamide is a member of the phthalazine class of compounds.
SYM2206 is a noncompetitive allosteric antagonist of AMPA receptors. It was used alongside another AMPA receptor antagonist, GYKI52466, to demonstrate that pharmacological inhibition of glutamate receptor signaling reduces the viability of pancreatic cancer cells, suggesting a potential therapeutic approach for pancreatic cancer [2]. |
| Molecular Formula |
C20H22N4O3
|
|
|---|---|---|
| Molecular Weight |
366.41
|
|
| Exact Mass |
366.169
|
|
| CAS # |
173952-44-8
|
|
| Related CAS # |
|
|
| PubChem CID |
5039877
|
|
| Appearance |
Light yellow to yellow solid powder
|
|
| Density |
1.37g/cm3
|
|
| Index of Refraction |
1.673
|
|
| LogP |
3.591
|
|
| Hydrogen Bond Donor Count |
2
|
|
| Hydrogen Bond Acceptor Count |
5
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
27
|
|
| Complexity |
576
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
CCCNC(=O)N1C(C2=CC3=C(C=C2C(=N1)C4=CC=C(C=C4)N)OCO3)C
|
|
| InChi Key |
OFUDZKKOKPGXOH-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C20H22N4O3/c1-3-8-22-20(25)24-12(2)15-9-17-18(27-11-26-17)10-16(15)19(23-24)13-4-6-14(21)7-5-13/h4-7,9-10,12H,3,8,11,21H2,1-2H3,(H,22,25)
|
|
| Chemical Name |
8-(4-aminophenyl)-5-methyl-N-propyl-5H-[1,3]dioxolo[4,5-g]phthalazine-6-carboxamide
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (7.51 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (7.51 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7292 mL | 13.6459 mL | 27.2918 mL | |
| 5 mM | 0.5458 mL | 2.7292 mL | 5.4584 mL | |
| 10 mM | 0.2729 mL | 1.3646 mL | 2.7292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
GRIA2/3 is expressed in pancreatic cancer, and glutamate receptor modulators affect pancreatic cancer cell viability.Neoplasia.2010 Aug;12(8):659-67. |
|---|
GRIA3 enhances tumor cellNeoplasia.2010 Aug;12(8):659-67. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
